Zimmer Biomet Holdings, Inc. Stock 12‑Month Price Target Raised to $108.15, Implies 11% Upside

What happened

Estimates from 20 analysts put Zimmer Biomet Holdings’ average 12-month share-price target at $108.15, up from $105.75, with forecasts ranging from $93 to $125. Based on the Nov. 3 closing price, the new target implies about 11% potential upside; the rating consensus remains Hold among 30 analysts.

Confirmed

Global impact / market context

The higher target signals that the analysts supplying estimates see more potential share-price upside than before, but it is not a forecast of guaranteed returns. The unchanged Hold consensus, including 21 Holds, indicates that the broader analyst group has not shifted to a generally positive rating.

Analyst inference

The article reports analyst expectations and ratings, not new information about Zimmer Biomet’s sales, costs, cash available, or business outlook. The 11% figure compares the target with the Nov. 3 closing price, so it describes implied upside rather than a realized gain.

Confirmed

What to watch

1. Watch whether later analyst targets move beyond the current $93–$125 range; a sustained rise or fall would show changing views on the share-price outlook. Analyst inference
2. The reported ratings total 8 Buys, 21 Holds and 1 Sell among 30 analysts; a change in this balance could signal a broader shift in analyst opinion. Confirmed
3. Compare future target changes with any company updates on sales, costs, or cash available; those operating results could clarify whether analysts’ higher price expectation has business support. Analyst inference

Evidence

• Original source link unavailable